US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8012472B2
(en)
|
2002-12-23 |
2011-09-06 |
William Marsh Rice University |
Compositions and methods for suppressing fibrocytes
|
JP4819364B2
(ja)
|
2002-12-23 |
2011-11-24 |
ウイリアム、マーシュ、ライス、ユーニヴァーサティ |
線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物
|
WO2007094776A1
(en)
*
|
2006-02-15 |
2007-08-23 |
William Marsh Rice University |
Compositions and methods for suppressing fibrocyte differentiation
|
US7763256B2
(en)
|
2002-12-23 |
2010-07-27 |
William Marsh Rice University |
Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
|
US7355008B2
(en)
*
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
NZ545776A
(en)
|
2003-08-22 |
2009-05-31 |
Biogen Idec Inc |
Improved antibodies having altered effector function and methods for making the same
|
US7687265B2
(en)
*
|
2003-11-25 |
2010-03-30 |
The General Hospital Corporation |
Foxn1 and pigmentation
|
KR101297146B1
(ko)
*
|
2004-05-10 |
2013-08-21 |
마크로제닉스, 인크. |
인간화 FcγRIIB 특이적 항체 및 그의 사용 방법
|
WO2006033702A2
(en)
|
2004-07-26 |
2006-03-30 |
Biogen Idec Ma Inc. |
Anti-cd154 antibodies
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
ZA200701783B
(en)
*
|
2004-09-02 |
2009-10-28 |
Genentech Inc |
Anti-Fc-gamma RIIB receptor antibody and uses therefor
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
KR101027427B1
(ko)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체
|
CA2590935C
(en)
*
|
2004-12-15 |
2014-09-30 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
EP1674479A1
(en)
*
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
EP1835935A4
(en)
*
|
2004-12-30 |
2009-06-17 |
Univ Rockefeller |
COMPOSITIONS AND METHODS FOR IMPROVED DENDRITIC CELL REPRODUCTION AND FUNCTION
|
WO2006110593A2
(en)
*
|
2005-04-07 |
2006-10-19 |
Macrogenics, Inc. |
Biological targets for the diagnosis, treatment and prevention of cancer
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
*
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
US8217147B2
(en)
*
|
2005-08-10 |
2012-07-10 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
BRPI0619586A2
(pt)
*
|
2005-12-09 |
2018-08-28 |
Seattle Genetics Inc |
método para o tratamento ou prevenção de um distúrbio associado com cd40
|
US9109223B2
(en)
*
|
2005-12-23 |
2015-08-18 |
Viventia Bio, Inc. |
Methods for generating and screening fusion protein libraries and uses thereof
|
EP1999470A4
(en)
*
|
2006-03-10 |
2009-08-19 |
Macrogenics Inc |
IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
WO2008105886A2
(en)
*
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
EP2032159B1
(en)
*
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
HUE030269T2
(en)
*
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
CA2664333A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Memorial Sloan Kettering Cancer Center |
Methods of diagnosing, treating, or preventing plasma cell disorders
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
US8247370B2
(en)
|
2006-12-04 |
2012-08-21 |
Promedior, Inc. |
Conjoint therapy for treating fibrotic diseases
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
CN101821288A
(zh)
|
2007-06-21 |
2010-09-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
US8497243B2
(en)
|
2007-07-06 |
2013-07-30 |
Promedior, Inc. |
Methods and compositions useful in the treatment of mucositis
|
US9884899B2
(en)
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
US20090176654A1
(en)
|
2007-08-10 |
2009-07-09 |
Protelix, Inc. |
Universal fibronectin type III binding-domain libraries
|
US8470966B2
(en)
|
2007-08-10 |
2013-06-25 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
US8680019B2
(en)
|
2007-08-10 |
2014-03-25 |
Protelica, Inc. |
Universal fibronectin Type III binding-domain libraries
|
MX369784B
(es)
|
2007-09-26 |
2019-11-21 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
KR101397554B1
(ko)
*
|
2007-11-09 |
2014-05-21 |
재단법인서울대학교산학협력재단 |
치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
|
WO2009117030A2
(en)
*
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
PL2247304T3
(pl)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
|
CN106349390B
(zh)
|
2008-04-02 |
2019-12-10 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
DK2708559T3
(en)
|
2008-04-11 |
2018-06-14 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
|
WO2010033279A2
(en)
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
CN106432503B
(zh)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
共价双抗体及其用途
|
JP5797565B2
(ja)
|
2009-03-11 |
2015-10-21 |
プロメディオール, インコーポレイテッド |
過敏性障害(hypersensitive disorder)に対する処置および診断方法
|
CA2755047C
(en)
|
2009-03-11 |
2018-12-04 |
Promedior, Inc. |
Treatment methods for autoimmune disorders
|
EA201101572A1
(ru)
*
|
2009-04-27 |
2012-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
|
UA110323C2
(en)
|
2009-06-04 |
2015-12-25 |
Promedior Inc |
Derivative of serum amyloid p and their receipt and application
|
ES2552793T3
(es)
|
2009-06-17 |
2015-12-02 |
Promedior Inc. |
Variantes de SAP y su uso
|
TW201110973A
(en)
*
|
2009-06-25 |
2011-04-01 |
Shiseido Co Ltd |
Methods for screening for anti-graying agents on the basis of AFF-4
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
RU2583298C2
(ru)
|
2009-10-07 |
2016-05-10 |
Макродженикс, Инк. |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
EP2543727B1
(en)
*
|
2010-03-02 |
2016-08-31 |
Kyowa Hakko Kirin Co., Ltd. |
Modified antibody composition
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
NZ602161A
(en)
|
2010-03-04 |
2014-12-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
JP5964300B2
(ja)
|
2010-08-02 |
2016-08-03 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
GB201013989D0
(en)
*
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
WO2012074097A1
(ja)
*
|
2010-12-03 |
2012-06-07 |
協和発酵キリン株式会社 |
抗cd33抗体
|
BR112013021526B1
(pt)
*
|
2011-02-25 |
2021-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
|
WO2012133782A1
(ja)
*
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
KR20190105112A
(ko)
|
2011-05-21 |
2019-09-11 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
BR112014013081A2
(pt)
|
2011-11-30 |
2020-10-20 |
Chugai Seiyaku Kabushiki Kaisha |
veículo contendo fármaco em célula para formação de um complexo imune
|
US20160046693A1
(en)
*
|
2012-02-24 |
2016-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc gamma RIIB
|
RU2743463C2
(ru)
|
2012-05-30 |
2021-02-18 |
Чугаи Сейяку Кабусики Кайся |
Специфичная к ткани-мишени антигенсвязывающая молекула
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
CA2882272C
(en)
|
2012-08-24 |
2023-08-29 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc region variant
|
ES2876009T3
(es)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Polipéptido heterodimerizado
|
EP3255062B1
(en)
|
2013-02-14 |
2019-07-03 |
Innate Pharma |
Anti-nkp46 antibody for diganosis of a non-cutaneous peripheral t-cell lymphoma (ptcl)
|
EP2958941B1
(en)
|
2013-02-20 |
2019-04-10 |
Innate Pharma |
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
MX2015012709A
(es)
|
2013-03-14 |
2016-05-31 |
Macrogenics Inc |
Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
EP2837637A1
(en)
*
|
2013-08-16 |
2015-02-18 |
SuppreMol GmbH |
Novel anti-FcyRIIB IgG-type antibody
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
EP3763813A1
(en)
|
2013-12-04 |
2021-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
|
US10280222B2
(en)
|
2014-03-14 |
2019-05-07 |
Innate Pharma |
Humanized antibodies with increased stability
|
CA2952727A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific nkp46 binding proteins
|
CA2952532A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
WO2016023985A1
(en)
*
|
2014-08-13 |
2016-02-18 |
Suppremol Gmbh |
Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
EP3201227A4
(en)
|
2014-09-29 |
2018-04-18 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
US10329348B2
(en)
|
2014-10-23 |
2019-06-25 |
Innate Pharma |
Treatment of cancers using anti-NKG2A agents
|
JP6227191B1
(ja)
|
2014-12-19 |
2017-11-08 |
中外製薬株式会社 |
抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
SG11201706786UA
(en)
*
|
2015-03-18 |
2017-09-28 |
Seattle Genetics Inc |
Cd48 antibodies and conjugates thereof
|
CA2990511A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific antigen binding proteins
|
WO2016207278A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
EP3430047A1
(en)
|
2016-03-15 |
2019-01-23 |
Innate Pharma |
Anti-mica antibodies
|
KR102514317B1
(ko)
|
2016-04-15 |
2023-03-27 |
마크로제닉스, 인크. |
신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
|
JP6527643B2
(ja)
|
2016-08-05 |
2019-06-05 |
中外製薬株式会社 |
Il−8関連疾患の治療用又は予防用組成物
|
US20190248895A1
(en)
|
2016-10-21 |
2019-08-15 |
Innate Pharma |
Treatment with anti-kir3dl2 agents
|
WO2018115262A1
(en)
|
2016-12-23 |
2018-06-28 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
US10767164B2
(en)
|
2017-03-30 |
2020-09-08 |
The Research Foundation For The State University Of New York |
Microenvironments for self-assembly of islet organoids from stem cells differentiation
|
US11634488B2
(en)
|
2017-07-10 |
2023-04-25 |
International—Drug—Development—Biotech |
Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
AU2018371114A1
(en)
|
2017-11-21 |
2020-05-07 |
Innate Pharma |
Multispecific antigen binding proteins
|
KR20210119454A
(ko)
|
2019-01-22 |
2021-10-05 |
이나뜨 파르마 에스.에이. |
T 세포 림프종의 치료
|
MX2023011310A
(es)
|
2021-03-26 |
2023-10-05 |
Innate Pharma |
Anclajes de citocina para proteinas de celulas nk de union a nkp46.
|
EP4352098A1
(en)
|
2021-06-09 |
2024-04-17 |
Innate Pharma |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
BR112023025476A2
(pt)
|
2021-06-09 |
2024-02-27 |
Innate Pharma |
Proteína de ligação multimérica e seu método de produção, composição farmacêutica, molécula de ácido nucleico isolada, vetor de expressão, célula isolada e proteína de ligação para uso
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|